TIGEBAX INJ

Antibacterial

Description
Shipping Options
Customer Reviews

TIGEBAX INJ is a broad-spectrum glycylcycline antibiotic containing Tigecycline, used for complicated infections caused by multi-drug resistant (MDR) bacteria when other treatments fail.

Composition

Active Ingredient: Tigecycline 50 mg (as lyophilized powder).
Inactive Ingredients: Hydrochloric acid, sodium hydroxide, lactose monohydrate.

Mechanism of Action

Bacteriostatic (inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit).
Covers:
- Gram-positive (MRSA, VRE*, Streptococcus)
- Gram-negative (E. coli, Klebsiella, Acinetobacter)
- Anaerobes (Bacteroides fragilis)
- Atypicals (Mycoplasma, Legionella)
Not effective against: Pseudomonas aeruginosa, Proteus spp.

(Limited activity against some Enterococcus faecium strains)*

Dosage & Administration

Adults:

Loading dose: 100 mg IV (single dose).
Maintenance: 50 mg IV every 12 hours (infuse over 30–60 minutes).
Duration: Typically 5–14 days (based on infection severity).

Hepatic Impairment (Child-Pugh C):

Reduce maintenance dose to 25 mg every 12 hours.

Renal Impairment:

No dose adjustment needed (not renally excreted).

Pediatrics:

Not recommended (risk of tooth discoloration & bone growth issues).

Indications (Approved Uses)

1️⃣ Complicated Skin & Soft Tissue Infections (cSSTI) 2️⃣ Complicated Intra-Abdominal Infections (cIAI) 3️⃣ Community-Acquired Bacterial Pneumonia (CABP) 4️⃣ Severe MDR infections (when alternatives fail).

(Not approved for diabetic foot infections or bacteremia due to higher mortality risk.)

Storage & Stability

Unreconstituted vials: Store at 20–25°C, protect from light.
Reconstituted solution:
- Stable for 6 hrs at room temp or 24 hrs if refrigerated (2–8°C).
Do not freeze or shake vigorously.

Key Recommendations

✔ Last-line antibiotic (use only when other options fail). ✔ Monitor liver enzymes (risk of hepatotoxicity). ✔ Watch for superinfections (C. difficile, fungal). ✔ Avoid in pregnancy (Category D) – fetal risks.

Black Box Warning (FDA Alert)

⚠ Higher mortality risk observed in clinical trials (especially in HAP). ⚠ Use only when no safer alternatives exist.

Side Effects

Common: Nausea, vomiting, diarrhea, headache.
Serious:
- Acute pancreatitis.
- Liver toxicity.
- Severe hypersensitivity.

Drug Interactions

Warfarin → Increased bleeding (monitor INR).
Oral contraceptives → Reduced efficacy (use backup).
PPIs → May affect absorption if switching to oral therapy.

Conclusion

TIGEBAX INJ (Tigecycline) is a critical reserve antibiotic for MDR infections. Strict monitoring is essential due to safety risks.

Composition

Active Ingredient: Tigecycline 50 mg (as lyophilized powder).
Inactive Ingredients: Hydrochloric acid, sodium hydroxide, lactose monohydrate.

Mechanism of Action

Bacteriostatic (inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit).
Covers:
- Gram-positive (MRSA, VRE*, Streptococcus)
- Gram-negative (E. coli, Klebsiella, Acinetobacter)
- Anaerobes (Bacteroides fragilis)
- Atypicals (Mycoplasma, Legionella)
Not effective against: Pseudomonas aeruginosa, Proteus spp.

(Limited activity against some Enterococcus faecium strains)*

Dosage & Administration

Adults:

Loading dose: 100 mg IV (single dose).
Maintenance: 50 mg IV every 12 hours (infuse over 30–60 minutes).
Duration: Typically 5–14 days (based on infection severity).

Hepatic Impairment (Child-Pugh C):

Reduce maintenance dose to 25 mg every 12 hours.

Renal Impairment:

No dose adjustment needed (not renally excreted).

Pediatrics:

Not recommended (risk of tooth discoloration & bone growth issues).

Indications (Approved Uses)

1️⃣ Complicated Skin & Soft Tissue Infections (cSSTI)
2️⃣ Complicated Intra-Abdominal Infections (cIAI)
3️⃣ Community-Acquired Bacterial Pneumonia (CABP)
4️⃣ Severe MDR infections (when alternatives fail).

(Not approved for diabetic foot infections or bacteremia due to higher mortality risk.)

Storage & Stability

Unreconstituted vials: Store at 20–25°C, protect from light.
Reconstituted solution:
- Stable for 6 hrs at room temp or 24 hrs if refrigerated (2–8°C).
Do not freeze or shake vigorously.

Key Recommendations

✔ Last-line antibiotic (use only when other options fail).
✔ Monitor liver enzymes (risk of hepatotoxicity).
✔ Watch for superinfections (C. difficile, fungal).
✔ Avoid in pregnancy (Category D) – fetal risks.

Black Box Warning (FDA Alert)

⚠ Higher mortality risk observed in clinical trials (especially in HAP).
⚠ Use only when no safer alternatives exist.

Side Effects

Common: Nausea, vomiting, diarrhea, headache.
Serious:
- Acute pancreatitis.
- Liver toxicity.
- Severe hypersensitivity.

Drug Interactions

Warfarin → Increased bleeding (monitor INR).
Oral contraceptives → Reduced efficacy (use backup).
PPIs → May affect absorption if switching to oral therapy.

Conclusion

TIGEBAX INJ (Tigecycline) is a critical reserve antibiotic for MDR infections. Strict monitoring is essential due to safety risks.

Shipping Options –

We offer a variety of shipping options, including Express Mail Service (EMS), USPS, DHL, FedEx, TNT, UPS, Aramex, Air Cargo, and sea freight.

Terms and Conditions –

Bulk Orders: You are responsible for any local import duties and taxes in your country.

For Patients: When ordering prescription medicines for personal use, or for a friend or relative, a valid medical practitioner’s script or prescription is required.

Return and Refund Policy: Due to the nature of our products, we cannot accept returns or exchanges once a purchase is made. However, in the event of non-delivery, you are eligible for either a 100% refund or a reshipment of your order.

Description
Reviews (0)

Composition

Active Ingredient: Tigecycline 50 mg (as lyophilized powder).
Inactive Ingredients: Hydrochloric acid, sodium hydroxide, lactose monohydrate.

Mechanism of Action

Bacteriostatic (inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit).
Covers:
- Gram-positive (MRSA, VRE*, Streptococcus)
- Gram-negative (E. coli, Klebsiella, Acinetobacter)
- Anaerobes (Bacteroides fragilis)
- Atypicals (Mycoplasma, Legionella)
Not effective against: Pseudomonas aeruginosa, Proteus spp.

(Limited activity against some Enterococcus faecium strains)*

Dosage & Administration

Adults:

Loading dose: 100 mg IV (single dose).
Maintenance: 50 mg IV every 12 hours (infuse over 30–60 minutes).
Duration: Typically 5–14 days (based on infection severity).

Hepatic Impairment (Child-Pugh C):

Reduce maintenance dose to 25 mg every 12 hours.

Renal Impairment:

No dose adjustment needed (not renally excreted).

Pediatrics:

Not recommended (risk of tooth discoloration & bone growth issues).

Indications (Approved Uses)

1️⃣ Complicated Skin & Soft Tissue Infections (cSSTI)
2️⃣ Complicated Intra-Abdominal Infections (cIAI)
3️⃣ Community-Acquired Bacterial Pneumonia (CABP)
4️⃣ Severe MDR infections (when alternatives fail).

(Not approved for diabetic foot infections or bacteremia due to higher mortality risk.)

Storage & Stability

Unreconstituted vials: Store at 20–25°C, protect from light.
Reconstituted solution:
- Stable for 6 hrs at room temp or 24 hrs if refrigerated (2–8°C).
Do not freeze or shake vigorously.

Key Recommendations

✔ Last-line antibiotic (use only when other options fail).
✔ Monitor liver enzymes (risk of hepatotoxicity).
✔ Watch for superinfections (C. difficile, fungal).
✔ Avoid in pregnancy (Category D) – fetal risks.

Black Box Warning (FDA Alert)

⚠ Higher mortality risk observed in clinical trials (especially in HAP).
⚠ Use only when no safer alternatives exist.

Side Effects

Common: Nausea, vomiting, diarrhea, headache.
Serious:
- Acute pancreatitis.
- Liver toxicity.
- Severe hypersensitivity.

Drug Interactions

Warfarin → Increased bleeding (monitor INR).
Oral contraceptives → Reduced efficacy (use backup).
PPIs → May affect absorption if switching to oral therapy.

Conclusion

TIGEBAX INJ (Tigecycline) is a critical reserve antibiotic for MDR infections. Strict monitoring is essential due to safety risks.

Reviews

There are no reviews yet.

Be the first to review “TIGEBAX INJ”

Description
Reviews (0)

Composition

Active Ingredient: Tigecycline 50 mg (as lyophilized powder).
Inactive Ingredients: Hydrochloric acid, sodium hydroxide, lactose monohydrate.

Mechanism of Action

Bacteriostatic (inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit).
Covers:
- Gram-positive (MRSA, VRE*, Streptococcus)
- Gram-negative (E. coli, Klebsiella, Acinetobacter)
- Anaerobes (Bacteroides fragilis)
- Atypicals (Mycoplasma, Legionella)
Not effective against: Pseudomonas aeruginosa, Proteus spp.

(Limited activity against some Enterococcus faecium strains)*

Dosage & Administration

Adults:

Loading dose: 100 mg IV (single dose).
Maintenance: 50 mg IV every 12 hours (infuse over 30–60 minutes).
Duration: Typically 5–14 days (based on infection severity).

Hepatic Impairment (Child-Pugh C):

Reduce maintenance dose to 25 mg every 12 hours.

Renal Impairment:

No dose adjustment needed (not renally excreted).

Pediatrics:

Not recommended (risk of tooth discoloration & bone growth issues).

Indications (Approved Uses)

1️⃣ Complicated Skin & Soft Tissue Infections (cSSTI)
2️⃣ Complicated Intra-Abdominal Infections (cIAI)
3️⃣ Community-Acquired Bacterial Pneumonia (CABP)
4️⃣ Severe MDR infections (when alternatives fail).

(Not approved for diabetic foot infections or bacteremia due to higher mortality risk.)

Storage & Stability

Unreconstituted vials: Store at 20–25°C, protect from light.
Reconstituted solution:
- Stable for 6 hrs at room temp or 24 hrs if refrigerated (2–8°C).
Do not freeze or shake vigorously.

Key Recommendations

✔ Last-line antibiotic (use only when other options fail).
✔ Monitor liver enzymes (risk of hepatotoxicity).
✔ Watch for superinfections (C. difficile, fungal).
✔ Avoid in pregnancy (Category D) – fetal risks.

Black Box Warning (FDA Alert)

⚠ Higher mortality risk observed in clinical trials (especially in HAP).
⚠ Use only when no safer alternatives exist.

Side Effects

Common: Nausea, vomiting, diarrhea, headache.
Serious:
- Acute pancreatitis.
- Liver toxicity.
- Severe hypersensitivity.

Drug Interactions

Warfarin → Increased bleeding (monitor INR).
Oral contraceptives → Reduced efficacy (use backup).
PPIs → May affect absorption if switching to oral therapy.

Conclusion

TIGEBAX INJ (Tigecycline) is a critical reserve antibiotic for MDR infections. Strict monitoring is essential due to safety risks.

Reviews

There are no reviews yet.

Be the first to review “TIGEBAX INJ”

Medical Disclaimer

Anteka Pharmacy primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Anteka Pharmacy. Our mission is to support, not replace, the doctor-patient relationship.